30 within month
50+ within year
Takeda has made significant moves in the development of it's global pipeline. From the MASSIVE moves with various COVID vaccine manufacturers, to acquiring smaller Immunology biotech startups, and increase in Boston research sphere. I am the most bullish on Takeda purely from a fundamental standpoint.
Institutional ownership is low compared to other pharma's (AZN ~15%, Pfizer 66%), which would be extremely worrying, except I view it as less big movers to the stock, more tiny movers, which can make volatility rather high, but if this recent consumer-approach of holding longer on to a stock, then I take this over the risk of BoA deciding it isn't worth it to them anymore. Furthermore, ARK has >20million shares, and we can all agree that Cathie Wood is a genius.
They just brought on their first non-Japanese CEO, who has publicly announced a more global-centric development platform. This isn't a sudden change in Takeda, this is the culmination of that shift. They have been stepping more and more into the Boston science sphere, with more and more of that to be expected as they continue to build up their Boston staff.
As of the time of writing, TAK sits at 18.86 with a 42 cent change in share price with todays announcement of very positive phase 3 clinical trial news, and J&J COVID vaccine manufacturing deal. I expect very big gains very soon, as investors find more and more news at EOD research cycle, followed by the pump and dump crew hopping on. As new analyst outlooks come out, I expect a $50+ evaluation, possibly mimicking recent biotech movements of 100% very quickly.
This is my first published idea, I would love feedback! If you want to see any additions, such as the pipeline and disease relevance data, I can definitely add that for Takeda. I plan to continue publishing in smaller biotech's, as I am just starting to get into investing my own money, and my scientific background, namely in the Boston-biotech sphere.
This is in no way financial advise, and as I am new to price predictions, I am following very very basic rules, but I will refine and develop my personal algorithm for price evaluations due to real market fundamentals such as drug market valuations, etc.
Thank you for your time, and please remember, I am not a financial advisor, this is my personal biased view on this company's stock valuation, please do your own due diligence so you are making decisions based on your own knowledge and beliefs!